Ribosomal and immune transcripts associate with relapse in acquired ADAMTS13-deficient thrombotic thrombocytopenic purpura

Contessa E. Edgar, Deirdra R. Terrell, Sara K. Vesely, Jonathan D. Wren, Igor M. Dozmorov, Timothy B. Niewold, Michael Brown, Fang Zhou, Mark Barton Frank, Joan T. Merrill, Johanna A. Kremer Hovinga, Bernhard Lä Mmle, Judith A. James, James N. George, A. Darise Farris

Research output: Contribution to journalArticle

Abstract

Approximately 40% of patients who survive acute episodes of thrombotic thrombocytopenic purpura (TTP) associated with severe acquired ADAMTS13 deficiency experience one or more relapses. Risk factors for relapse other than severe ADAMTS13 deficiency and ADAMTS13 autoantibodies are unknown. ADAMTS13 autoantibodies, TTP episodes following infection or type I interferon treatment and reported ensuing systemic lupus erythematosus in some patients suggest immune dysregulation. This cross-sectional study asked whether autoantibodies against RNA-binding proteins or peripheral blood gene expression profiles measured during remission are associated with history of prior relapse in acquired ADAMTS13-deficient TTP. Peripheral blood from 38 well-characterized patients with autoimmune ADAMTS13-deficient TTP in remission was examined for autoantibodies and global gene expression. A subset of TTP patients (9 patients, 24%) exhibited a peripheral blood gene signature composed of elevated ribosomal transcripts that associated with prior relapse. A non-overlapping subset of TTP patients (9 patients, 24%) displayed a peripheral blood type I interferon gene signature that associated with autoantibodies to RNA-binding proteins but not with history of relapse. Patients who had relapsed bimodally expressed higher HLA transcript levels independently of ribosomal transcripts. Presence of any one potential risk factor (ribosomal gene signature, elevated HLA-DRB1, elevated HLA-DRB5) associated with relapse (OR = 38.4; p = 0.0002) more closely than any factor alone or all factors together. Levels of immune transcripts typical of natural killer (NK) and T lymphocytes positively correlated with ribosomal gene expression and number of prior episodes but not with time since the most recent episode. Flow cytometry confirmed elevated expression of cell surface markers encoded by these transcripts on T and/or NK cell subsets of patients who had relapsed. These data associate elevated ribosomal and immune transcripts with relapse history in acquired, ADAMTS13-deficient TTP.

Original languageEnglish (US)
Article numbere0117614
JournalPloS one
Volume10
Issue number2
DOIs
StatePublished - Feb 11 2015

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • General

Fingerprint Dive into the research topics of 'Ribosomal and immune transcripts associate with relapse in acquired ADAMTS13-deficient thrombotic thrombocytopenic purpura'. Together they form a unique fingerprint.

  • Cite this

    Edgar, C. E., Terrell, D. R., Vesely, S. K., Wren, J. D., Dozmorov, I. M., Niewold, T. B., Brown, M., Zhou, F., Frank, M. B., Merrill, J. T., Kremer Hovinga, J. A., Lä Mmle, B., James, J. A., George, J. N., & Farris, A. D. (2015). Ribosomal and immune transcripts associate with relapse in acquired ADAMTS13-deficient thrombotic thrombocytopenic purpura. PloS one, 10(2), [e0117614]. https://doi.org/10.1371/journal.pone.0117614